Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

call at www.lexpharma.com. An archived version of the webcast will be available on the website through March 21, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements", including statements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon To Present At The BIO CEO & Investor Conference
2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Lexicon to Provide Third Quarter 2012 Financial Results
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
9. Lexicon to Provide Second Quarter 2012 Financial Results
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
...  Aria Diagnostics, a molecular diagnostics company, today announced ... examines the accuracy of its non-invasive prenatal test ... Down syndrome) and Trisomy 18 (associated with Edwards ... with a proprietary algorithm to assess individualized risk ...
... Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that ... of Gastrodia valued at 67.5 Million RMB or approximately ... Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and ... of Gastrodia from January 1, 2012 to December 31, 2012. ...
Cached Medicine Technology:Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Center for BrainHealth will bring together national experts ... challenges at its inaugural Brain Health Summit, titled ... speakers will include Dr. Sandra Bond Chapman, founder ... U.S. Senator Chuck Grassley (R-IA), U.S. Representative Chaka ... for Policy and Early Learning, U.S. Department of ...
(Date:4/24/2014)... to be boring and irrelevant, could offer an alternative ... Researcher Dr Milena Furtado, and her team from the ... the heart cell fibroblast is a close relative to ... heart. , In research published today in Circulation ... are unique cells due to their genetic program, and ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2
... day, March 20, we celebrate head injury awareness day. This ... annual incidences of head injuries. Every day, 500,000 people are ... or the other and it is the sixth most common cause ... globe in the U.S, every 15 seconds, a person suffers a ...
... this time. Beer, wine and spirits bottles will now be ... trying to conceive. The decision follows fears over ... officials warn of subsequent risks such as fetal alcohol syndrome ... have been protests from the liquor lobby that say that ...
... ‘disgusting’ reports that reveal millions of pounds being collected in ... , The figures disclosed under the Freedom of ... pounds being made during 2005/2006,some trusts raised more than one ... charges" on the weak and vulnerable. The top ...
... has undergone liver transplant is convalescing well. This was ... Russell Britz the Head of the Transplant Unit at ... minister needed this liver transplant very urgently and that ... operation done. ,The Measure for End Stage ...
... provide quality care to patients. In a recent report, ... scan results never reach the doctors table. The report ... ,Worse still, the results reach Doctors via informal ... a tacit agreement between the department and the Doctor ...
... persistent asthma have a level of control that is ... the journal of Ambulatory Pediatrics. ,"That leaves almost ... to," said the study's lead author, Jill Halterman, M.D., ... at Strong. "They may be experiencing unnecessary symptoms, missed ...
Cached Medicine News:Health News:Head Injury Awareness Day 2Health News:Head Injury Awareness Day 3Health News:Babies and Drinks Don’t Mi 2Health News:Easy Money-NHS Trusts Make Millions from Parking Fees 2Health News:Asthmatic Children Still Not Breathing Easier, Study Says 2
Large deep curve....
3 mm electrode Inserts - monopolar foot control connection....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: